<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366988</url>
  </required_header>
  <id_info>
    <org_study_id>2012_43</org_study_id>
    <secondary_id>2013-A01671-44</secondary_id>
    <nct_id>NCT02366988</nct_id>
  </id_info>
  <brief_title>The PASTEC Study: Endoscopic Stenting Versus Surgery for the Treatment of Bile Duct Stricture in Chronic Pancreatitis</brief_title>
  <acronym>PASTEC</acronym>
  <official_title>Phase 3 Prospective, Multicentric Randomized Study of Endoscopic Versus Surgical Treatment of Bile Duct Stricture in Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biliary obstruction complicates the course of chronic pancreatitis in 3%-23% of patients and
      in these cases, endoscopy and surgery are the treatment modalities of choice.
      Morbid-mortality of these procedures is similar and physicians face the decision between
      endoscopy and surgery for this group of patients, with no randomized controlled trial
      available comparing these procedures.

      The PASTEC trial is a multicenter, phase III, randomized, comparing the effectiveness of
      surgical and endoscopic interventions in the management of bile duct stricture for chronic
      pancreatitis.

      The primary end point is 18-months normalization of serum alkaline phosphatase. Secondary end
      points are morbid-mortality rate, quality of life, numbers of endoscopic or surgical
      procedures, length of stay. Eighty-six patients need to be included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is planned to last for 4 years, with a 2-year inclusion period and a 2-year
      follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>normalization of serum alkaline phosphatase (considered as &lt; 130 UI/L)</measure>
    <time_frame>18 months</time_frame>
    <description>A normal value of serum alkaline phosphatase will be considered as &lt; 130 UI/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EORTC health surveys)</measure>
    <time_frame>At 18 months</time_frame>
    <description>EORTC health surveys will administered to assess quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal pain (Clinical symptoms assessed by Izbicki's score)</measure>
    <time_frame>at 1, 3, 6, 12,18 months after the procedure</time_frame>
    <description>Clinical symptoms assessed by Izbicki's score,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>jaundice, (Clinical symptoms assessed)</measure>
    <time_frame>at 1, 3, 6, 12,18 months after the procedure</time_frame>
    <description>Clinical symptoms assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pruritus, (Clinical symptoms assessed)</measure>
    <time_frame>at 1, 3, 6, 12,18 months after the procedure</time_frame>
    <description>Clinical symptoms assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pale stool, (Clinical symptoms assessed)</measure>
    <time_frame>at 1, 3, 6, 12,18 months after the procedure</time_frame>
    <description>Clinical symptoms assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dark urine. (Clinical symptoms assessed)</measure>
    <time_frame>at 1, 3, 6, 12,18 months after the procedure</time_frame>
    <description>Clinical symptoms assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholestasis</measure>
    <time_frame>At 1, 3, 6, 12, 18 months after the procedure</time_frame>
    <description>Biological measures Cholestasis Bilirubinemia &lt; 1,2 mg/dl (norms : 0,1 à 1,2 mg / dl) Gamma GT &lt; 50 UI / L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytolysis</measure>
    <time_frame>At 1, 3, 6, 12, 18 months after the procedure</time_frame>
    <description>Biological measures Cytolysis TGO &lt; 40 UI / L (norms : 15 à 40 UI / L) TGP &lt; 40 UI / L (norms : 10 à 40 UI / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver failure</measure>
    <time_frame>At 1, 3, 6, 12, 18 months after the procedure</time_frame>
    <description>Biological measures Liver failure TP &gt; 60% (norms : 60 à 120%) Facteur V &gt; 60% (norms : 60 à 120%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT-Scan (Morphological assessment)</measure>
    <time_frame>At 6 and 18 months after the procedure</time_frame>
    <description>Morphological assessment by CT-Scan, Pseudocyst, main pancreatic duct &gt; 3 mm, inflammatory cephalic mass &gt; 4 cm, biliary duct stricture, pancreatic calcifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bili-MRI</measure>
    <time_frame>At 6 and 18 months after the procedure</time_frame>
    <description>Morphological assessment by Bili-MRI, Pseudocyst, main pancreatic duct &gt; 3 mm, inflammatory cephalic mass &gt; 4 cm, biliary duct stricture, pancreatic calcifications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of surgical complications ( dindo and Clavien )</measure>
    <time_frame>At 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>At 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of re - hospitalization</measure>
    <time_frame>At 1, 3, 6, 12, 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Endoscopic Biliary Stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temporary self-expandable metallic covered stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surgical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic Biliary Stenting</intervention_name>
    <description>Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months</description>
    <arm_group_label>Endoscopic Biliary Stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical treatment Bilio-enteric anastomosis</intervention_name>
    <description>Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation</description>
    <arm_group_label>Surgical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical symptomatic chronic pancreatitis-related biliary duct stricture (pain or
             jaundice or pale stool / dark urine)

          -  Biological symptomatic chronic pancreatitis-related biliary duct stricture (elevation
             of serum alkaline phosphatase (&gt;2 or 3 times the upper limit of normal values) and/or
             of serum bilirubin for longer than 1 month)

          -  Isolated biliary stricture or biliary stricture associated to main pancreatic duct
             stricture

          -  Secondary biliary cirrhosis

          -  Progression of biliary stricture

        Exclusion Criteria:

          -  Pancreatic malignancy

          -  Cirrhosis

          -  Portal vein thrombosis, portal cavernoma

          -  Primary sclerosing cholangitis

          -  Recent acute pancreatitis (i.e., in the previous 3 weeks)

          -  Acute hepatitis

          -  Post-surgical biliary stricture

          -  Biliary stones or pseudocyst-related biliary duct stricture

          -  Previous pancreatic surgery or endoscopic sphincterotomy

          -  Score IV or V on the American Society of Anesthesiologists scale

          -  Pregnancy or breastfeeding

          -  Patient aged under 18 yrs

          -  Emergency clinical situations (i.e., angiocholitis with septicemia)

          -  Non-compliant patients or suffering from legal incapacity

          -  Contra-indication for endoscopic or surgical treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ZERBIB, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe ZERBIB, M.D, PhD</last_name>
    <email>philippe.zerbib@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christophe PLANE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thierry PAUPARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Dr Schaffner</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachid DJEDIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Louvière</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Bulois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Philibert</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Damien LUCIDARME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud Duriez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier</name>
      <address>
        <city>Valencienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud BORUCHOWICZ, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2015</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Bile stricture</keyword>
  <keyword>Endoscopy</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

